novel parp inhibitor boosts pfs in her2– breast cancer with brca mutations
Published 6 years ago • 171 plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
3:53
mbcc 2017: multiple parp inhibitors show promise in breast cancer treatment
-
2:47
what is a parp inhibitor? | dana-farber cancer institute | science illustrated
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
3:58
brca breast cancer: the advent of parp inhibitors
-
7:04
testing for brca germline mutations in the clinic and the mechanism of action of parp inhibitors
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today
-
1:52
parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer
-
4:19
treating brca breast cancer with parp inhibition
-
3:31
distinguishing between parp inhibitors in breast cancer
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
13:20
parp inhibitors for early, brca-mutant breast cancer - medpage today
-
4:59
future role of parp inhibition in brca breast cancer
-
2:17
rare cancer in the news 22/08/2022 - parp inhibitors and brca positive breast and ovarian cancers
-
4:11
brca breast cancer: managing patients on parp inhibitors
-
4:10
the embraca trial for advanced breast cancer, a new parp inhibitor
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
1:10
managing metastatic breast cancer and beyond using parp inhibitors
-
9:21
dr. litton on activity of talazoparib in advanced brca1/2 breast cancer
-
3:04
advances in parp inhibitor use for metastatic breast cancer